Deerland facility achieves Australia’s Therapeutic Goods Administration Certification
Deerland Probiotics & Enzymes now has Australia’s Therapeutic Goods Administration Certification at its Kennesaw, GA facility.
Photo © iStockphoto.com/volk65
Deerland Probiotics & Enzymes (Kennesaw, GA) now has Australia’s Therapeutic Goods Administration (TGA) Certification at its Kennesaw facility. This demonstrates that Deerland has manufacturing management practices and systems in that are in compliance with manufacturing standards established by the Australian Government Department of Health and Ageing. With an existing certification renewal at Deerland’s Forsyth, MO facility and a mutual recognition agreement with Australia at the newly acquired Denmark-based Bifodan A/S facility, all of Deerland’s facilities are now TGA certified.
TGA certification is also recognized and accepted by other governments worldwide. “This achievement is a key milestone for Deerland and is reflective of our entire team’s commitment to quality,” said Scott Ravech, CEO of Deerland, in a press release.
“The TGA audits are on par with U.S. pharmaceutical audits,” adds Hope Hanley, vice president of quality and regulatory affairs at Deerland. “They perform a stringent evaluation of the manufacturing facility, engineering, cleanliness, SOPs, and Quality Systems to ensure product integrity.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
